Healthcare, Pharma & Life Sciences

Holon, Israel – October 06, 2026 -- Compugen Ltd. (NASDAQ: CGEN; TASE: CGEN) will join a fireside chat at the H.C. Wainwright 3rd Annual AI Based Drug Discovery & Development Conference, a virtual event running October 8-9, 2026.

Management confirms October 8 session with live investor webcast

The fireside chat is scheduled for Thursday, October 06, 2026, at 9:30 AM ET. A live webcast will stream via the Investor Relations events page on Compugen's website, with a replay available afterward.

Dallas – October 06, 2026 -- Nanoscope Therapeutics will present four-year durability data from its RESTORE Phase 2b/3 trial of optogenetic therapy MCO-010 in retinitis pigmentosa at the American Academy of Ophthalmology (AAO) 2026 Annual Meeting, running October 8–13 in New Orleans.

Four-year REMAIN data to show durability of vision gains in retinitis pigmentosa

Dr. Kenneth C. Fan will present the REMAIN study results on Sunday, October 11, highlighting sustained vision improvement among patients treated with MCO-010 in the RESTORE trial. A separate scientific poster from Dr. David S. Boyer will detail vision improvement with sonpiretigene isteparvovec in dry age-related macular degeneration, drawn from what the company describes as the first direct-to-Phase 2 randomized controlled trial in that indication.

Barcelona – October 06, 2026 -- Veeva Systems (NYSE: VEEV) said its Data Quality System (DQS) has aggregated and cleaned data for more than 1 million subjects across over 1,000 clinical studies, automating over 500,000 queries and eliminating thousands of hours of manual data reconciliation for sites and sponsors.

Veeva DQS automates over 500,000 queries to speed analysis-ready data delivery

The platform classifies and visualizes critical trial data while orchestrating risk-based actions across the clinical ecosystem, removing manual reconciliation steps that have historically slowed data lock and submission timelines.

Novo cites rising trial data volume as key driver for automated data management

Ibrahim Kamstrup-Akkaoui, vice president at Novo, said managing data from a growing number of clinical trials is a priority, and that Veeva DQS helps the company manage, format, clean, and prepare data for submission more efficiently.

San Diego – October 06, 2026 -- Viking Therapeutics (NASDAQ: VKTX) has initiated Part 2 of a maintenance dosing study for VK2735, its dual GLP-1/GIP receptor agonist, testing oral tablet regimens alongside subcutaneous options to sustain weight loss after initial treatment.

Trial enrolls 195 obese adults to test five maintenance pathways

The randomized, double-blind, placebo-controlled study will enroll approximately 195 adults with obesity (BMI ≥30 kg/m2). All participants first receive 21 weeks of weekly subcutaneous VK2735 or placebo before transitioning to one of five maintenance arms: daily oral doses, weekly oral doses, monthly subcutaneous doses, every-other-week subcutaneous doses, or placebo. The study runs through Week 33, tracking safety, tolerability, pharmacokinetics, and body weight change from baseline and from Week 21.

Hallandale Beach, Fla. – October 06, 2026 -- NextPlat Corp (NASDAQ: NXPL) has completed its acquisition of an independent pharmacy in a rural community near Pensacola, Florida, for total cash consideration of $1,485,439.

Acquired pharmacy generated $5.6 million in sales last year

The Pharmacy posted approximately $5.6 million in sales for the year ended December 31, 2025. It was profitable, maintained positive working capital, and operated with a debt-free balance sheet at the time of purchase.

Notre Dame, Ind. – October 06, 2026 -- Researchers at the University of Notre Dame are building an AI system called Voice4PIMD to translate the facial expressions, gestures, eye gaze, and vocalizations of nonverbal individuals into text or audio alerts caregivers can act on.

Cameras and sensors capture nonverbal cues for caregiver training

Led by computer engineering scientist Jarek Nabrzyski, the team's system uses cameras and sensors to record facial expressions, eye gaze, body movements, heart rate, and vocalizations. Caregivers train the model to interpret these signals for a specific individual, since the same gesture can carry different meanings from person to person.

Cary, N.C. – October 06, 2026 -- SAS has been named to Fast Company's Next Big Things in Tech 2026 list in the Applied AI category for digital twin technology deployed by Sterilcentral, Denmark's largest medical sterilization provider, to manage instrument flow across seven hospitals supporting roughly 1,000 surgeries daily in the Danish capital region.

SAS built a 3D digital twin of Sterilcentral's Herlev facility to track thousands of instruments daily

The digital twin, built on SAS Viya and enhanced with 3D environments from Epic Games' Unreal Engine, models the washing, drying, packaging and delivery stages where instruments move through the facility. SAS and Sterilcentral used the system to locate and resolve disruptions in the sterilization pipeline that were previously difficult to isolate.

St. Louis – – October 06, 2026 -- Americans pay 422% more than patients in other countries for brand-name prescription drugs, according to RAND Corporation data, a gap that prescription-access firm SHARx is now targeting through an athlete-led awareness campaign called Rising Tides.

SHARx builds an ambassador network from personal relationships, not paid endorsement deals

CEO and co-founder Corey Durbin assembled the Rising Tides roster through direct connections rather than traditional sponsorship outreach. WNBA player Sophie Cunningham joined after University of Missouri broadcaster Mike Kelly introduced her to the cause. Former NFL quarterback Brock Osweiler met Durbin on a driving range before SHARx entered the conversation, and professional golfer Gary Hallberg linked Durbin to fellow golfer Steve Jones. Former NFL quarterback and three-term U.S. congressman Heath Shuler has also joined the initiative.

Fountain Valley, Calif. – October 06, 2026 -- Sunshine Retirement Living has closed the sale of Park View Estates, a 150-unit assisted living and memory care community in Fountain Valley, California, with the transaction completed on October 1, 2026.

Sunshine developed the community from entitlement through operations before the sale

Sunshine led design, construction, staffing and day-to-day management of the property at 11360 Warner Avenue, which welcomed its first resident on February 1, 2021. The company's involvement spanned the full lifecycle of the asset, from ground-up development to ongoing operations.

Dover, Delaware – October 06, 2026 -- The Digital CMC Consortium has launched as a new industry collaboration aimed at the end-to-end digitalization of Chemistry, Manufacturing, and Controls (CMC) processes in drug development. Founding participants include Novartis, Thermo Fisher Scientific, Takeda, Rockwell Automation, Flagship's Pioneering Medicines, Stellix, ZS Associates, and QbDVision.

Consortium targets legacy PDF-based workflows that bottleneck drug development

The CMC phase of pharmaceutical development remains tethered to manual, document-based processes that treat PDF tables as the source of truth, despite rapid advances in drug discovery and clinical trial digitization elsewhere in the industry. The Consortium aims to convert static CMC knowledge into reusable, interoperable digital assets to improve speed, quality, and regulatory confidence.